Selective peroxisome proliferator-activated receptor γ (PPARγ) modulation as a strategy for safer therapeutic PPARγ activation

Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial

2005 • 4,040 citations

Glycemic Durability of Rosiglitazone, Metformin, or Glyburide Monotherapy

2006 • 2,850 citations

Ligand binding and co-activator assembly of the peroxisome proliferator-activated receptor-γ

1998 • 1,902 citations

The PPARs: From Orphan Receptors to Drug Discovery

2000 • 1,792 citations

Thiazolidinediones

2004 • 1,755 citations

The Many Faces of PPARγ

2005 • 1,362 citations

Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial

2009 • 1,337 citations

International Union of Pharmacology. LXI. Peroxisome Proliferator-Activated Receptors

2006 • 974 citations

PPAR and human metabolic disease

2006 • 809 citations

Efficacy and Safety of the Human Glucagon-Like Peptide-1 Analog Liraglutide in Combination With Metformin and Thiazolidinedione in Patients With Type 2 Diabetes (LEAD-4 Met+TZD)

2009 • 808 citations

Congestive heart failure and cardiovascular death in patients with prediabetes and type 2 diabetes given thiazolidinediones: a meta-analysis of randomised clinical trials

2007 • 692 citations

Thiazolidinedione Use, Fluid Retention, and Congestive Heart Failure

2004 • 578 citations

Treatment of insulin resistance with peroxisome proliferator–activated receptor γ agonists

2000 • 535 citations

Long-term use of thiazolidinediones and fractures in type 2 diabetes: a meta-analysis

2008 • 529 citations

The Effect of Adding Exenatide to a Thiazolidinedione in Suboptimally Controlled Type 2 Diabetes

2007 • 436 citations

Divergent Effects of Selective Peroxisome Proliferator-Activated Receptor-γ2 Ligands on Adipocyte Versus Osteoblast Differentiation

2002 • 426 citations

Adiponectin in insulin resistance: lessons from translational research

2009 • 382 citations

Peroxisome Proliferator-Activated Receptors

2003 • 373 citations

Vildagliptin in combination with pioglitazone improves glycaemic control in patients with type 2 diabetes failing thiazolidinedione monotherapy: a randomized, placebo‐controlled study*

2006 • 277 citations

Fibroblast growth factor 21: from pharmacology to physiology

2009 • 202 citations

Thiazolidinediones, Peripheral Edema, and Type 2 Diabetes: Incidence, Pathophysiology, and Clinical Implications

2003 • 201 citations

Selective Modulators of PPAR-<mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML"><mml:mi>γ</mml:mi></mml:math>Activity: Molecular Aspects Related to Obesity and Side-Effects

2007 • 115 citations

INT131: A Selective Modulator of PPARγ

2009 • 106 citations

Halofenate Is a Selective Peroxisome Proliferator–Activated Receptor γ Modulator With Antidiabetic Activity

2006 • 96 citations

MBX-102/JNJ39659100, a Novel Peroxisome Proliferator-Activated Receptor-Ligand with Weak Transactivation Activity Retains Antidiabetic Properties in the Absence of Weight Gain and Edema

2009 • 78 citations

The Development of INT131 as a Selective PPARγ Modulator: Approach to a Safer Insulin Sensitizer

2008 • 77 citations

Thiazolidinediones for the treatment of type 2 diabetes

2007 • 77 citations

Selective Modulators of PPAR Activity as New Therapeutic Tools in Metabolic Diseases

2006 • 73 citations

Combined Thiazolidinedione-Insulin Therapy

2004 • 72 citations

Pioglitazone and sulfonylureas: effectively treating type 2 diabetes

2007 • 49 citations

Peroxisome proliferator-activated receptor translational research and clinical experience

2009 • 41 citations

Dual PPAR α/γ Agonists: Promises and Pitfalls in Type 2 Diabetes

2007 • 31 citations

Model‐Based Development of a PPARγ Agonist, Rivoglitazone, to Aid Dose Selection and Optimize Clinical Trial Designs

2008 • 23 citations

MBX-102/JNJ39659100, a Novel Non-TZD Selective Partial PPAR- Agonist Lowers Triglyceride Independently of PPAR- Activation

2009 • 21 citations

From bench to bedside: novel mechanisms and therapeutic advances through the development of selective peroxisome proliferator-activated receptor γ modulators

2009 • 18 citations

MBX-102/JNJ39659100, a Novel Peroxisome Proliferator Activated Receptor-γ Ligand with Weak Transactivation Activity Retains Full Anti-Diabetic Properties in the Absence of Side Effects

2009 • 3 citations

Cited By (0)

Loading...